Please assess the completion status of the following clinical trial:

Trial Title: Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed relapsed or refractory PTCL or NK/T-cell lymphomas, excluding primary cutaneous T-cell lymphoma, and Sezary syndrome based on WHO classification,~* Age ≥ 19~* ECOG performance status ≤ 2~* at least one bi-dimensional measurable lesion~* Laboratory values~  * Serum Cr \< 1.5 mg/dL or CrCl \> 50 mL/min~ * Transaminase (AST/ALT) \< 2.5 x ULN (or \< 5 x ULN in the presence of lymphoma involvement of the liver)~ * Bilirubin \< 1.5 x UNL ( or \< 3 x ULN in the presence of lymphoma involvement of the liver or Gilbert syndrome)~ * PT (INR) ≤ 1.5 x ULN and aPTT ≤ 1.5 x ULN~ * Lipase ≤ 1.5 x ULN~ * Hematologic functions: absolute neutrophil count (ANC) ≥ 1,500/µL and platelet count ≥ 75,000/µL, hemoglobin ≥ 8 g/dL~* Left ventricular ejection fraction (LVEF) ≥ the lower limit of normal for the institution~* Women of childbearing potential and men must agree to use adequate contraception when sexually active~* Written informed consent~Exclusion Criteria:~* B-cell NHL, or primary cutaneous T-cell lymphoma and Sezary syndrome~* Patients who had previous history of lymphoma involvement of the CNS.~* History of previous gemcitabine therapy~* Type I or II diabetes mellitus with HbA1c \> 8.5% at screening~* History of chronic hepatitis B; subjects positive for HBsAg will be excluded from this study. However, subjects with HBcAb will be eligible if they are negative for HBV DNA quantification~* History of chronic hepatitis C; subjects positive for HCV IgG will be eligible if they are negative for HCV-RNA quantification~* Known history of human immunodeficiency virus (HIV) infection~* History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function~* Any other malignancies within the past 3 years except curatively treated basal cell carcinoma of the skin, carcinoma in situ of the uterine cervix, or papillary carcinoma of the thyroid~* Other serious illness or medical conditions~  * Congestive heart failure \> NYHA class 2 (Appendix III)~ * Unstable angina or new-onset angina within the last 3 months; Myocardial infarction within 6 months prior to study entry~ * History of significant neurological or psychiatric disorders including dementia or seizure~ * Uncontrolled hypertension despite optimal medical management (per investigator's opinion)~ * Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before start of study treatment~ * Non-healing wound, ulcer, or bone fracture~ * Active uncontrolled infection (viral, bacterial, or fungal infection)~ * Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ grade 3 within 4 weeks of start of study medication~ * Proteinuria estimated by urine protein/creatinine ratio \> 3.5 on a random urine sample~ * Concurrent diagnosis of pheochromocytoma~* Other previous or concurrent treatments~  * Ongoing immunosuppressive therapy~ * Radiotherapy or immune-/chemotherapy less than 4 weeks before start of treatment~ * Radioimmunotherapy or autologous transplant less than 3 months before start of treatment~ * Myeloid growth factors within 14 days prior to treatment start~ * Blood or platelet transfusion within 7 days prior to treatment start~ * Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent~ * History of having received an allogeneic bone marrow or organ transplant~ * Major surgical procedure or significant trauma injury within 28 days before start of study medication, open biopsy within 7 days before start of study treatment~ * Anti-arrhythmic therapy (beta-blockers or digoxin are permitted)~ * Use of CYP3A4 inhibitor or inducer~* Pregnant or lactating women, women of childbearing potential not employing adequate contraception~* Concomitant administration of any other experimental drugs under investigation

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copanlisib/gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).